Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland
Ragnar Olafsson, Karól Kvaran, Kristín Ketilsdóttir, Kolbrún Hallgrímsdóttir, Engilbert Sigurðsson, Engilbert Sigurðsson
Læknablaðið November 3, 2023 DOI: 10.17992/lbl.2023.11.766 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Online survey Peer reviewed |
|---|---|
| Sample size | 256 |
| Population | Icelandic psychiatrists, general practitioners, and psychologists |
| Topics | Psilocybin |
| Keywords | Mental health Family medicine |
| Citations | 5 |
| Key findings | Most Icelandic mental health professionals reported little knowledge of psychedelics and negative attitudes toward psilocybin treatment, but supported further research and education. |
Abstract
Introduction: Interest in the use of psychedelics has increased following reports of their possible therapeutic potential. However, little is known about the knowledge of and attitudes towards the substances among health care professional who provide treatment for mental disorders in Iceland. An online survey was therefore conducted among members of the Icelandic associations of psychiatrists, general practitioners and psychologists.
Methods: Respondents were 256 in total, including 177 psychologists, 38 psychiatrists and 41 general practitioners that provided information on their background, type of work, knowledge of and attitude towards different types of psychedelic substances and their views on optimal service delivery if psychedelics were approved by licencing authorities and used for treatment.
Results: Around half of psychiatrists reported having received questions about treatment with psychedelics in their clinical work, compared to only 14,6% of general practitioners and 17,5% of psychologists. The majority of respondents had little, or no knowledge of the substances targeted in the survey. A majority also expressed negative attitudes towards treatment with psilocybin mushrooms, but was positive towards ongoing scientific research and felt that such a treatment should be prescribed and provided by psychiatrists. Moreover, the majority view was that psilocybin treatment should be provided in specialised clinics or psychiatric units in a hospital setting. Scientific articles on the topic, discussions with colleagues and information in the media were identified as having had most influence on respondents´ attitudes towards psychedelics. Most respondents were interested in further education on psychedelics.
Conclusions: Respondents among these three professions felt that the time has not yet come to use psychedelics in the treatment of mental disorders in Iceland but thought more education on psychedelics, their potential efficacy and adverse health effects is important given the increased interest in psychedelics.
Comparable studies
Other cross-sectional and survey studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... | 2016 | Cross-sectional survey | n = 1,993 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... | 2019 | Cross-sectional survey | n = 343 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
Citations in the library
Cited by 4
- Amid magic and menace: psychiatrists’ attitudes to psilocybin therapy Irish Journal of Psychological Medicine November 7, 2024
- Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study Journal of Psychoactive Drugs June 23, 2025
- Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need. Current Psychiatry Reports December 1, 2024
- Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA SAIMSARA Journal June 15, 2026
Cites 21
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Journal of Neuroscience November 30, 2020
- Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development Frontiers in Pharmacology July 5, 2018
and 16 more in the library